163 related articles for article (PubMed ID: 35094795)
1. Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers.
Enzing JJ; Himmler S; Knies S; Brouwer WBF
Value Health; 2022 Feb; 25(2):222-229. PubMed ID: 35094795
[TBL] [Abstract][Full Text] [Related]
2. Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals.
Koopmanschap MA; Stolk EA; Koolman X
Int J Technol Assess Health Care; 2010 Apr; 26(2):198-204. PubMed ID: 20392324
[TBL] [Abstract][Full Text] [Related]
3. Decision-makers' preferences for approving new medicines in Wales: a discrete-choice experiment with assessment of external validity.
Linley WG; Hughes DA
Pharmacoeconomics; 2013 Apr; 31(4):345-55. PubMed ID: 23516033
[TBL] [Abstract][Full Text] [Related]
4. Do Health Technology Assessment organisations consider manufacturers' costs in relation to drug price? A study of reimbursement reports.
Enzing JJ; Knies S; Engel J; IJzerman MJ; Sander B; Vreman R; Boer B; Brouwer WBF
Cost Eff Resour Alloc; 2022 Aug; 20(1):46. PubMed ID: 36045377
[TBL] [Abstract][Full Text] [Related]
5. Finding legitimacy for the role of budget impact in drug reimbursement decisions.
Niezen MG; de Bont A; Busschbach JJ; Cohen JP; Stolk EA
Int J Technol Assess Health Care; 2009 Jan; 25(1):49-55. PubMed ID: 19126251
[TBL] [Abstract][Full Text] [Related]
6. Methodological quality of economic evaluations of new pharmaceuticals in The Netherlands.
Hoomans T; Severens JL; van der Roer N; Delwel GO
Pharmacoeconomics; 2012 Mar; 30(3):219-27. PubMed ID: 22074610
[TBL] [Abstract][Full Text] [Related]
7. Health economic evaluations in reimbursement decision making in the Netherlands: time to take it seriously?
Franken M; Koopmanschap M; Steenhoek A
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):383-9. PubMed ID: 25444296
[TBL] [Abstract][Full Text] [Related]
8. On the role of cost-effectiveness thresholds in healthcare priority setting.
Siverskog J; Henriksson M
Int J Technol Assess Health Care; 2021 Jan; 37():e23. PubMed ID: 33491617
[TBL] [Abstract][Full Text] [Related]
9. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
[TBL] [Abstract][Full Text] [Related]
10. Drug Policy in the Czech Republic.
Skoupá J
Value Health Reg Issues; 2017 Sep; 13():55-58. PubMed ID: 29073989
[TBL] [Abstract][Full Text] [Related]
11. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
[TBL] [Abstract][Full Text] [Related]
12. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium.
Van Wilder P; Pirson M; Dupont A
Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328
[TBL] [Abstract][Full Text] [Related]
13. Public funding of pharmaceuticals in The Netherlands: investigating the effect of evidence, process and context on CVZ decision-making.
Cerri KH; Knapp M; Fernandez JL
Eur J Health Econ; 2014 Sep; 15(7):681-95. PubMed ID: 23864365
[TBL] [Abstract][Full Text] [Related]
14. Supporting the Development of Evidence-Informed Policy Options: An Economic Evaluation of Hypertension Management in Ghana.
Gad M; Lord J; Chalkidou K; Asare B; Lutterodt MG; Ruiz F
Value Health; 2020 Feb; 23(2):171-179. PubMed ID: 32113622
[TBL] [Abstract][Full Text] [Related]
15. Societal Preferences for Interventions with the Same Efficiency: Assessment and Application to Decision Making.
Shiroiwa T; Saito S; Shimozuma K; Kodama S; Noto S; Fukuda T
Appl Health Econ Health Policy; 2016 Jun; 14(3):375-85. PubMed ID: 26940671
[TBL] [Abstract][Full Text] [Related]
16. Eliciting preferences for medical devices in South Korea: A discrete choice experiment.
Lee HJ; Bae EY
Health Policy; 2017 Mar; 121(3):243-249. PubMed ID: 28117075
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries.
Franken M; Stolk E; Scharringhausen T; de Boer A; Koopmanschap M
Health Policy; 2015 Feb; 119(2):195-202. PubMed ID: 25456017
[TBL] [Abstract][Full Text] [Related]
18. Assessing social preferences in reimbursement negotiations for new Pharmaceuticals in Oncology: an experimental design to analyse willingness to pay and willingness to accept.
Wettstein DJ; Boes S
BMC Health Serv Res; 2021 Mar; 21(1):234. PubMed ID: 33726735
[TBL] [Abstract][Full Text] [Related]
19. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
[TBL] [Abstract][Full Text] [Related]
20. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
